Although drug interactions with Acarbose are uncommon, there is a possibility for\r\ninterference with the pharmacokinetic behaviors of concomitantly administered drugs. The\r\npresent study was designed to evaluate the possible drug interactions between Acarbose\r\nand orally administered MTZ. Twelve healthy volunteers and twelve diabetic patients were\r\nenrolled in a randomized controlled crossover study. The effect of Acarbose (single\r\n100mg dose) on the pharmacokinetics of MTZ was evaluated, while the effect of multiple\r\ndoses was evaluated only in diabetic patients. In both groups, 5ml blood samples were\r\ncollected into plane tubes at 0, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0\r\nand 48.0 hrs; serum levels of MTZ were evaluated using HPLC technique. The results\r\nshowed that diabetes mellitus significantly altered the pharmacokinetic parameters of\r\norally administered MTZ compared to healthy subjects. Moreover, both single and multiple\r\ndoses of Acarbose significantly changed the pharmacokinetic parameters of MTZ when\r\nused concomitantly. The pharmacokinetics of orally administered MTZ was significantly\r\naffected by both diabetes mellitus and concomitant use of single or multiple doses of\r\nAcarbose.
Loading....